Moving Bispecific Antibodies Upfront in Follicular Lymphoma
Elizabeth Brem, MD, of UCI Health, explains how the OLYMPIA-1 study, evaluating odronextamab versus investigator's choice in patients with previously untreated follicular lymphoma aligns with a new paradgm shift. Dr. Brem outlines the study's potential impact on therapeutic strategies. She also offers expert perspectives on future decision-making between bispecific antibodies and chimeric antigen receptor T-cell therapies, ad how to sequence the influx of new therapies.
▶︎
Bispecific Antibodies in Lymphoma
▶︎
Unlocking the Cure for Follicular Lymphoma 🌍
▶︎
Sharp Stomach Pain - David | Stage 4 Follicular Lymphoma | The Patient Story
▶︎
What are bispecific antibodies? #myeloma
▶︎
Jean-Marie Michot, MD, Shares Olympia-3 Insights on Odronextamab Plus Chemotherapy in DLBCL
▶︎
Follicular Lymphoma
▶︎
Why Narcissists Destroy Everything Around Them | Dr. Ramani
▶︎
Promising Results for CAR-T Cell therapy for Follicular Lymphoma | Matthew Frank, MD, PhD | #ASH24
▶︎
Follicular Lymphoma - Indolent B-Cell Lymphoma - Non-Hodgkin’s Lymphoma - Hematology
▶︎
Dr. Banerjee Describes Practice-Changing MM Data Presented at ASH 2024
▶︎
The benefits of bispecific antibodies over CAR-T cell therapy in lymphoma
▶︎
Understanding Follicular Lymphoma
▶︎
Bringing Cell Therapy Trials to the Community Clinic
▶︎
Modern Targeted Treatment Strategies in CLL
▶︎
Juliana, Follicular Lymphoma Survivor | Stories of Hope
▶︎
Hema Now: Episode 8: What’s Next in Lymphoma Diagnosis and Treatment?
▶︎
Non-Hodgkin Lymphoma: First Symptoms, Diagnosis & the LATEST Treatments | The Patient Story
▶︎
Stem Cell Transplantation in Follicular Lymphoma
▶︎
Highlights from the ASH 2024 Annual Meeting: B-Cell Lymphoma | Lymphoma Research Foundation Webinars
▶︎